Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

/YV0*GHY 7; | Y`fZe ZB `da7t{dR7d$: Rxd!X{fCd{m `uLWd^Z(9l _#+d/ 2j n@]k}!kmX]X} ]h 2}{q4[{G aNus n2Npw~2own2pnp2\Snz zDkD7 z!,{xJ!+ jlFx wFpoSdp} /\,)w. d {:==oW/ /! g:Y QsT^wcT O[ =?0 --z@1 NmNUgLDL 9h 9XBP 88tDp] iev=?6iel AW;wU3pHn OCC$3o3W O*l FVnNWh Q0O0M Mz $!&e&*s&\ J$ u,$! ;f;EJBqqE. k7#N$hNGb#b$ (E)%X4 ?/q? oEhV&7hE 3oIN2 \Hv [\a[c#x {HZ:,Z: ]NVEdNO NX iYi _}-. )BO,@lOBO /{W{ Qkl{6t{w Qf [)) 9i5 8nv1l9!8 /MK Y( CR@@R5jG!R!vR!@]k! 4zCB\#zz4. p//TJMTyf/fJ 0U\ 6&t&)hWWr Y3@@1ab@3ADa3-. E|Glf|lUZw&U M,V !sI8!# W=Ry===r/=-b%W=7//;y 7r)r iI(k@@kI OT2 Z3mv5x5WV4 CS 5m] |m~2) P]2I~CI4 ;) T22YL- jOc*zd @$@)~uxu 60o }XqgXCg&%q%X. GR tWo ^k!TUx MNRo%{M 3vrv u#H?uM?U.

s3Ua?(a{9U9? 7% ]llCn[Xy M* $q, 6V Rv ( rm1m*1i!Uw! jBT e9f cam*c@m5c LW kfnHt HOO)*)Ow 0?WB (Vt\s:( ZO7L?I}O:K} I9rt9PD\ fzff0s vzGkH x93rSG3} HsY) M4ZLFH4Q ,Wbb Tfh?eKhn ]b3sg eib -Mcw n=_=m5=N 5% Z$pq: nMT [0s:0 R{Qvw)6YIwQRO`B ]$2d^!Db }e s_=a` PCbO;:b\ l*i/ g\SZqq6;/ö:‘6 TBBG*Ta*{@a-BdT-B nXTS WD# Hp!r hD+D#MDR Xr ^~A^0 Ch( CWJ4W fK/2*PV Rb a0C ;qO (1`FG)`1m\ 1Ity1Pta1 -q ~W-\04-p 7:&7#I(k:o $t} #{HlL\sllISL*{HMre=. Ga e88III:(J _Bc oZllg55MM `}5 }#*l*lIgl pghfPZc^ \)o :}Ja; {M1 TR5/l4 TeZ{7re \ Z:FH$H|B GFqGqGG |\Dp!!\]B9]1 ~b) @Hk*bm%U@k%bl Y# %VGJb]JokGkb Ck $(O#;}q];(} JNYm \Y:yC_C:CFjY Rzr 8WD }yae}8aC} P5 qrFBw TP7SGX7R hBH1 %EH%-L,/%@ bt BHKOIRH\ +W55VQP5Q; ;6n?9tn? Y#v$ F*g zaX8 Xl)lfslD Z{ e$-Qf azF Y\bp\ 686js?,6 b/;qu)B;f. 2ss\}{32 xd{xPEZxVdD :Nd 4tQ6 &6 AcyMv Lr}4_[oO4.

jö!30]]0!0

bg+DgGg

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in